KMT2D‐mediated H3K4me1 recruits YBX1 to facilitate triple‐negative breast cancer progression through epigenetic activation of c‐Myc

Documenti analoghi

• Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer
  di: Xiaojie Liang, et al.
  Pubblicazione: (2025)
• PCDHGB7 inhibits the progression of triple‐negative breast cancer by suppressing XRCC5/MYC‐mediated ribosome biogenesis
  di: Ming Shan, et al.
  Pubblicazione: (2025)
• TMEM92 shields DDX3X from TTC3‐mediated degradation to confer chemoresistance in triple‐negative breast cancer
  di: Hao Shen, et al.
  Pubblicazione: (2026)
• Siglec15/ TGF ‐β bispecific antibody mediates synergistic anti‐tumor response against 4T1 triple negative breast cancer in mice
  di: Limei Shen, et al.
  Pubblicazione: (2024)
• RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple‐negative breast cancer
  di: Shumei Huang, et al.
  Pubblicazione: (2025)